Abstract:Anti-TNF antibody has been an effective therapeutic strategy for the diseases related to aberrant production of TNF-alpha, such as rheumatoid arthritis (RA) and Crohn's disease. The limitations of large molecule inhibitors in the therapy of these diseases prompted the search for other potent novel TNF-alpha antagonists. Antagonistic peptides, derived directly or designed rationally from complementarity-determining regions (CDRs) of neutralizing antibodies against TNF-alpha, have been demonstrated for their ability of inhibiting TNF-alpha. However, their activity is very low. In this study, to increase the affinity and bioactivity, human antibody variable region was used as scaffold to display antagonistic peptides, which were designed on the interaction between TNF-alpha and its neutralizing monoclonal antibody (mAb Z12). Based on the previously designed domain antibody (framework V(H)5), framework V(kappa)1 was used as light chain scaffold. On the basis of computer-guided molecular design method, a novel human scFv fragment (named as TSA1) was designed. Theoretical analysis showed that TSA1 could bind to TNF-alpha with more hydrogen bonds and lower binding free energy than the designed domain antibody. The biological experiments demonstrated that TSA1 could directly bind with TNF-alpha, competitively inhibit the binding of mAb Z12 to TNF-alpha and block the binding of TNF-alpha to TNFR I and TNFR II. TSA1 could also inhibit TNF-induced cytotoxicity on L929 cells and TNF-mediated NF-kappaB activation on HEK-293T cells. The bioactivity of TSA1 was significantly increased over the domain antibody. This study indicated that the framework of antibody variable region could serve as an ideal scaffold for displaying the peptides and provides a novel strategy to design TNF-alpha inhibitors with the ability to block the deleterious biological effects of TNF-alpha.

A Novel Bivalent Single‐chain Variable Fragment (scfv) Inhibits the Action of Tumour Necrosis Factor Α

One-Step On-Column Purification And Refolding Of A Single-Chain Variable Fragment (Scfv) Antibody Against Tumour Necrosis Factor Alpha

A Novel Human Scfv Fragment Against Tnf-Alpha from De Novo Design Method

A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides

Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions

Novel human single chain antibody design based on the functional epitope of TNF

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

A Native-Like Bispecific Antibody Suppresses the Inflammatory Cytokine Response by Simultaneously Neutralizing Tumor Necrosis Factor-Alpha and Interleukin-17A

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α

Overexpression, Effective Renaturation, And Bioactivity Of Novel Single-Chain Antibodies Against Tnf-Alpha

Structural Basis for Treating Tumor Necrosis Factor Α (Tnfα)-Associated Diseases with the Therapeutic Antibody Infliximab

A novel single domain bispecific antibody targeting VEGF and TNF-α ameliorates rheumatoid arthritis

Fusion of HSA Influences TNF-α Neutralizing Activity of Shtnfrs

Fusion Protein of CDR Mimetic Peptide with Fc Inhibit TNF-α Induced Cytotoxicity

T0001, a Variant of TNFR2-Fc Fusion Protein, Exhibits Improved Fc Effector Functions Through Increased Binding to Membrane-Bound TNFα

Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo

Biological Activities of Human Tumor Necrosis Factor-Alpha and Its Novel Mutants.

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A

Detection of Biological Activity of Recombinant Human Tumor Necrosis Factor α Inhibitory Peptide Fused with Anti-Inflammatory Acidic Tail